MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Thomas Warner from Proactive after the Europe-based plant-inspired medicine company announced it has secured a US$1mln order from AMC Pharma for ArtemiC, an anti-inflammatory that is also shown to provide benefits to Covid sufferers. Clements gives an overview of the order and of the ArtemiC product, explaining that its "the OTC form of CimetrA, which is under development as an FDA new drug indication file." In March 2023, MGC Pharma revealed that ArtemiC had gained a spot on the National Drug Code Database as an OTC Unlicensed Drug, approved by the US FDA. Clements says that "we are pushing on as fast as we can and I think you'll hear more good news about some aspects of one or more of those products in the weeks and months ahead." MGC Pharmaceuticals says on its website that ArtemiC has been tested for safety and efficacy in a double-blind, placebo-controlled clinical trial of 50 patients diagnosed with COVID-19.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com